hospital machines at the kitchen table

hospital machines at the kitchen table

Problem statement

Medical devices originally designed for clinical environments — dialysis machines, infusion pumps, ventilators, optical coherence tomography systems — are rapidly migrating into patients' homes for self-administered care. However, these devices were engineered for settings with stable power, controlled lighting, trained operators, and immediate clinical backup. The home environment introduces uncontrolled variables that clinical validation never accounted for: power fluctuations, children and pets, variable lighting, disability, low health literacy, and no on-site troubleshooting support. The FDA has acknowledged that "very few at-home care options have considered the structural and critical elements of the home" required for safe operation, and no comprehensive human factors standard exists for home-use medical devices.

Why this matters

Millions of patients use home medical devices daily — dialysis machines, CPAP/BiPAP, oxygen concentrators, glucose monitors, infusion pumps — and this number is growing rapidly due to aging populations, chronic disease management, and pandemic-era care delivery shifts. Device-related adverse events in the home are likely significantly under-reported because patients may not recognize device failure as the cause of a problem, and adverse event reporting infrastructure is far less developed outside clinical settings.

What’s been tried and why it hasn’t worked

The FDA's existing home-use device guidance (a 2010 white paper and updated framework) focuses primarily on labeling and user instructions rather than design requirements adapted to the home environment. IEC 62366 provides general usability engineering guidance but does not specifically address home-environment hazards like non-standard electrical outlets, variable Wi-Fi, or cognitive impairments. The FDA invested $1.2 million in 2024 to build a VR model of a home environment to help developers understand physical constraints — an acknowledgment that the design-environment mismatch is real and unresolved. Individual De Novo authorizations for home-use devices (e.g., Notal Vision's home OCT in 2024) set device-specific conditions but do not establish generalizable home-use safety principles. The FDA sought public comment in 2024 on increasing patient access to at-home technologies, but no binding guidance or standards have yet been issued.

What would unlock progress

A comprehensive human factors framework specifically for home-use medical devices — covering environmental hazards, user capability ranges, fail-safe design requirements, and connectivity standards — would give manufacturers clear design targets. Validated testing protocols that simulate the diversity of real home environments (urban apartments, rural homes, assisted living facilities) would replace the current reliance on clinical-environment validation.

Entry points for student teams

Start with the adverse-event record that already exists and is free: FDA's MAUDE database, queryable through the openFDA device API, tags each report with an event location, and a search on `event_location:"Home"` returns tens of thousands of reports (57,114 as of August 2026), enough to build a failure taxonomy by device type and to show where report narratives point at environmental causes the reporting form has no field to capture. A team can then reach device users directly rather than through a hospital — CPAP, oxygen concentrator, and glucose monitor users are reachable through patient communities and support groups — and run interviews plus a photo diary of the device in the room where it actually lives, which yields environmental and workaround data without in-home research visits. A second team could prototype an environmental assessment toolkit — sensors and checklists that evaluate whether a specific home is suitable for a specific device before deployment — and validate it in student and family homes. Full in-home observation of home-dialysis patients is the study everyone wants, but it takes a nephrology partner, recruitment through their clinic, and an IRB willing to approve research visits to sick patients' homes; the semester deliverable there is the study's design and instrument, handed to a clinical partner to run.